TherapeuticsMD (TXMD) Misses Q4 EPS by 2c

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $18.68 million versus the consensus estimate of $28.98 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• DA Davidson Reiterates Neutral Rating on WW Grainger (GWW), Notes Tactical Upside Potential
• Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal